HIPO heads into its August 6 earnings release with a notable divergence: a stock up 12% over the past month but options traders growing more cautious by the session.
The sharpest signal into the print is in options. Demand for downside protection has climbed to near-annual-high levels, with the put/call ratio at 0.81 — almost two standard deviations above its 20-day mean of 0.30, and the second-highest reading of the past year. That kind of defensive rotation after a strong run suggests investors are hedging rather than pressing the long trade into results. The borrow market adds little alarm to that picture. Availability is extraordinarily loose at over 2,300% — meaning there are roughly 23 shares available to borrow for every one already lent out. Cost to borrow sits below 0.6%, barely changed in a week. The lending pool imposes no friction on would-be shorts. Short interest itself has climbed — up 54% over the past month to 3.4% of the free float — but that increase looks modest in absolute terms and faces no squeeze conditions from the borrow side.
The analyst debate heading in is split between cautious and constructive. B. Riley raised its target to $41.50 this morning, maintaining its Buy rating, pointing to the company's improving fundamentals. That contrasts with KBW, which has held a Market Perform rating through a long series of small target adjustments and only moved its target to $33 — now below the current price of $32.55. Hippo's factor scores argue forcefully for the bull case on near-term estimates: EPS momentum ranks in the 99th percentile over the past 30 days and the 97th percentile over 90 days, with a 93rd-percentile EPS surprise score. Where the bears have ground is valuation. The price-to-book has expanded, and EV/EBITDA has been compressing — down over 7 points in 30 days — as the stock has re-rated faster than earnings revisions have moved. On earnings history, the last print on June 2 saw the stock fall 7% on the day and 4.4% over the following five sessions; the most recent event in late July produced a 5.4% gain.
Insider activity has been consistently one-directional. CEO Rick McCathron sold shares in April, May, June, and again on July 9 — four sales across roughly 90 days, totalling around $435,000. CFO Guy Zeltser sold in May and again on July 28. Neither transaction was outsized in dollar terms, and the sales appear to follow a regular schedule, but the cadence is worth noting given the stock's strong run. The ORTEX short score has ticked up modestly from around 40 to 42 since July 23, a mild deterioration consistent with the short interest growth, but still well within a normal range.
Thursday's print is ultimately a test of whether Hippo's EPS momentum streak — one of the strongest in the sector — can hold against a valuation that has re-rated sharply higher while insiders have been steadily reducing exposure.
See the live data behind this article on ORTEX.
Open HIPO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
